Clinical trials: Thromboangiitis Obliterans
- Condition Thromboangiitis Obliterans
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Non-healing Wound, Thromboangiitis Obliterans
Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease
The purpose of this expanded access program (EAP) is to provide Selexipag (Uptravi) for the treatment of participant with non-healing wound, buerger's disease.
- Trial name
- NCT04914247
- Testing
- Selexipag
- Sponsor
- Actelion